Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZE2203 in advanced gynecological solid tumors
NCT06904131Phase 1Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZE2203, sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoint: Number of participants with treatment-related adverse events at 1 year. Started May 2025; status: recruiting.
02
Drugs
BZE2203
Beyond the preview
Go deeper on NCT06904131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904131.